U.S. flag

An official website of the United States government, Department of Justice.

Nevada FY 2023 PDMP Program

Award Information

Award #
15PBJA-23-GK-05231-PDMP
Funding Category
Competitive Discretionary
Location
Awardee County
NV
Congressional District
Status
Open
Funding First Awarded
2023
Total funding (to date)
$759,849

Description of original award (Fiscal Year 2023, $759,849)

The purpose of this proposal by Nevada State Board of Pharmacy is to enhance the Prescription Monitoring Program (PMP) to ensure compliance with the State’s mandatory use statute with a focus on addressing the growing problem of the over prescribing of Schedule II stimulants. Additionally, the proposal will also ensure highly qualified staff is available to continue programs to fight against prescription drug abuse and continue to make tools available to prescribers at the point of patient care. The primary activities include to produce and disseminate educational materials to Nevada’s top Schedule II stimulant providers to increase awareness of the risk stimulants may pose and how to identify and treat stimulant use disorder and overdoses. PMP data will be analyzed to identify the top 25 Schedule II stimulant prescribers every 6 months. Education materials will be disseminated to the top 25 prescribers to increase awareness of the growing stimulant problem in Nevada. The goal is to reduce the overall stimulant prescribing for each prescriber, also to monitor the Nevada PMP prescriber compliance with the use of advanced analytic tools by identifying practitioners who prescribed a controlled substance to a patient prior to the query and review of the patient’s PMP report, which is a requirement of the practitioner by State law. The PMP will disseminate reports to the practitioner’s licensing board as a notification of noncompliance and provide education to the practitioners identified by the advanced analytic tools. The goal is to increase practitioner PMP query compliance to 100%. Finally, to provide quality unsolicited reports of suspected fraudulent or otherwise unlawful or inappropriate prescribing patterns to authorized law enforcement agencies and/or occupational licensing boards for further investigation. PMP data will be analyzed to identify fraudulent, illegal, unauthorized or otherwise inappropriate activity relating to the prescribing, dispensing or use of controlled substances. The PMP data will also be analyzed to identify patients who are seeking duplicative medications from multiple prescribers (“doctor shoppers”) and prescribers who are unwitting victims of doctor shopping. The goal is to reduce drug diversion and other unlawful prescribing activities.

Date Created: September 28, 2023